Compare The Vita Coco Company Inc (COCO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Vita Coco Company Inc vs Novartis AG — how do they compare? The Vita Coco Company Inc trades at $74.45 (market cap $4.23B), while Novartis AG trades at $150.12 (market cap $288.65B). The key difference: Novartis AG is far larger — about 68.2× The Vita Coco Company Inc's market cap, and Novartis AG pays a 3.15% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| COCO | NVS | |
|---|---|---|
Market Cap | $4.23B | $288.65B |
Sector | Technology | Health |
52-Week High | $84.02 | $168.62 |
52-Week Low | $32.30 | $113.50 |
Enterprise Value | $4.04B | $328.67B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COCO trades at $74.635, up 4.53% today, with a bullish technical signal and strong earnings momentum after beating Q1 2026 EPS estimates. The company reported 37% YoY revenue growth in Q1 2026, with management raising full-year guidance. Analysts maintain a $78.00 consensus price target, with 60% recommending Buy. Key support lies at $72, with resistance at $76.
Outlook remains positive driven by international expansion and dominant market position, but elevated valuation multiples pose risks. Upside depends on sustained execution against raised guidance, while any earnings miss or margin pressure could trigger volatility. The stock offers growth exposure but requires monitoring of competitive and consumer spending trends.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
